PP
RNAC icon

Paloma Partners’s Cartesian Therapeutics RNAC Stock Holding History

Paloma Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,153
Closed -$166K – 2442
2019
Q3 		$166K Sell
3,153
-1,977
-39% -$105K ﹤0.01% 1785
2019
Q2 		$275K Buy
+5,130
New +$350K ﹤0.01% 1348

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's RNAC Position: Q4 2019 in Review

Paloma Partners sold out of Cartesian Therapeutics (RNAC) in Q4 2019, closing a stake of 3,153 shares — an estimated $166K sold.

Paloma Partners first reported a position in RNAC in Q2 2019 and held it in 2 quarters. The position peaked at $275K in Q2 2019. 38 funds tracked by Wall St. Rank hold RNAC as of Q4 2019.

  • Paloma Partners reported no remaining Cartesian Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Paloma Partners sold 3,153 Cartesian Therapeutics shares in Q4 2019, an estimated $166K.
  • Paloma Partners first reported a position in Cartesian Therapeutics in Q2 2019 and held it in 2 quarters.
  • Paloma Partners's Cartesian Therapeutics position peaked at $275K in Q2 2019.
  • 38 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.